Peptide education
Ovagen
Ovagen is usually the tripeptide Glu-Asp-Leu, abbreviated EDL, from the Khavinson bioregulator lineage. It is marketed as a liver peptide, but the evidence map does not match the marketing: the liver story lives in a Russian patent, while the strongest peer-reviewed biology is kidney cell and rodent kidney-injury work. The only human material anywhere in the record is one patent example. And at least one U.S. seller lists a different molecule, Lys-Glu-Leu, under the Ovagen name.
Ovagen's marketing is liver-first; its verifiable biology is kidney-first; its only human data point is a 34-patient example inside a patent. Before any claim can be weighed, the product has to be confirmed as actual EDL, because the same name is also attached to a different tripeptide.
Overview
Quick answer
Ovagen is not always the same product from one source to the next. The best-supported peptide identity is Glu-Asp-Leu, while at least one U.S. seller lists Lys-Glu-Leu under the same name. Those are different tripeptides, so sequence identity changes which evidence applies.
What is Ovagen?
In the bioregulator context, Ovagen means glutamyl-aspartyl-leucine, EDL. A Russian patent names H-Glu-Asp-Leu for liver regeneration, and the Saint Petersburg Institute sells Ovagen in its Cytogens line for liver and GI support.
Why is it discussed?
Three channels converge on one name: a patent claiming liver regeneration, institute and vendor marketing around liver, GI, and detox support, and peer-reviewed kidney papers reporting EDL effects in cell culture and rodent kidney-injury models. The channels reinforce each other less than the marketing implies.
What routes and amounts show up?
The patent is the only source with regimen detail: parenteral H-Glu-Asp-Leu in animal liver models, and a chronic-hepatitis example dosed intramuscularly for 10 days, with stated amounts jumping from 10 micrograms to 5 mg between moderate and severe disease, unexplained. U.S. vendors list 20 mg research vials; that is packaging, not a studied human schedule.
What should you check first?
The molecule. One U.S. listing maps Ovagen to Lys-Glu-Leu, a different tripeptide, and the patent's own chemistry line has a formula inconsistency. If the sequence is wrong, every downstream claim changes meaning.
Reported practice
Commonly reported protocol
No established community protocol. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
The liver-regeneration patent and one U.S. vendor listing support the EDL identity, while another seller lists a different tripeptide under the same Ovagen name.
The concrete human item is a chronic-hepatitis example inside the patent. No strong modern peer-reviewed human efficacy trial surfaced in these sources.
Liver-regeneration, hepatitis, cirrhosis, detox, and GI-support language comes from patent examples and institute or vendor marketing, not modern clinical confirmation.
Peer-reviewed papers report EDL-related effects in kidney cell cultures, organotypic rat kidney tissue, and rodent acute kidney injury models. That supports research interest, not a human nephrology claim.
Research-only sellers, sequence mismatch, formula inconsistencies, COA marketing, and class-level peptide concerns make identity, sterility, impurities, and lot documentation central issues for this name.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Ovagen is EDL, H-Glu-Asp-Leu. | Patient reports do not identify which tripeptide was in a product. The strongest identity support comes from the liver-regeneration patent and institute product materials. | EDL appears in Khavinson short-peptide literature and is listed in a review as Ovagen, with renal-cell, hepatoprotective, and DNA-binding themes. | U.S. vendor pages use the Ovagen name while disagreeing on sequence. One listing maps it to Lys-Glu-Leu, which is a different molecule. | Treat EDL as the identity when a source explicitly means H-Glu-Asp-Leu. Products sold as "Ovagen" can still point to a different tripeptide or a loose brand name. |
| Ovagen regenerates or repairs the liver. | The patent includes animal liver examples and a small chronic-hepatitis patient example, but that is not the same as modern peer-reviewed human confirmation. | The patent describes liver explants, rat partial hepatectomy, experimental cirrhosis, and reported biochemical changes. Those claims exist but remain patent-level support. | Institute and seller language keeps public Ovagen marketing centered on liver, gastrointestinal, detoxification, and organ-support themes. | The narrow version is fair: patent-described liver biology and marketing interest exist. Established human liver repair has not been shown in the reviewed modern sources for Ovagen. |
| Ovagen helps hepatitis or cirrhosis. | The patent reports a chronic-hepatitis example with daily intramuscular H-Glu-Asp-Leu for 10 days and claims symptom and lab improvement. The patent material lacks a contemporary trial report with the detail expected for a dependable treatment claim. | Patent animal examples in cirrhosis and liver regeneration make the topic biologically relevant, but treatment benefit in people has not been shown. | Institute marketing describes hepatitis, toxic exposures, antibiotic side effects, malnutrition, older adults, and liver support, but it does not provide enough methods to judge the clinical signal. | Mention this as patent and institute material. Hepatitis or cirrhosis treatment claims need much stronger clinical evidence. |
| Ovagen supports kidney function. | No human trial was found showing kidney-function improvement after Ovagen/EDL treatment. | Peer-reviewed kidney papers report effects on proliferation, p53, MMP-14, apoptosis-related readouts, antioxidant-enzyme activity, proteinuria, and renal-function markers in cell, tissue, and rodent injury models. | Kidney claims are less prominent in U.S. consumer marketing than liver claims, even though the available peer-reviewed EDL papers are strongest in kidney models. | Plausible as a preclinical research topic. These sources do not show it as a human kidney-support therapy. |
| Ovagen is an anti-aging, longevity, or mitochondrial peptide. | No available human evidence establishes Ovagen as a longevity, healthy-aging, cognitive, performance, or mitochondrial intervention. | Khavinson short-peptide papers discuss DNA, histones, gene expression, methylation-related processes, and ultrashort-peptide transport hypotheses. That explains why anti-aging claims appear, but a clinical longevity effect has not been shown. | Bioregulator marketing often drifts toward broad organ support and anti-aging language. Ovagen-specific material does not yet carry human outcome claims. | Weak and indirect. Discuss gene-expression and preclinical organ-model work, not longevity or mitochondrial enhancement as settled benefits. |
| Vendor COAs make Ovagen products reliable. | No human efficacy or safety study verifies current U.S. research vials as comparable to the patent material or institute product. | A peptide identity claim depends on the correct amino-acid sequence and analytical method. Here, public listings conflict between EDL and Lys-Glu-Leu, and the patent chemistry line itself has a formula/mass inconsistency. | Vendor listings may advertise third-party testing, purity, weight, and endotoxin checks while also stating research-only or not-for-human-use positioning. | A COA only helps with the Ovagen problem when it confirms the right molecule, representative lot, sterility expectations, endotoxin controls, impurities, storage, and chain of custody. |
Bottom line
Main takeaway
Ovagen is a short peptide sold on liver and kidney claims with almost no human evidence behind either. Treat it as a research name, not a therapy.
Keep the evidence lanes separate: the patent carries the liver claims, the peer-reviewed papers carry kidney biology, the institute page is marketing, and U.S. research vials mostly raise identity questions, including one listing with the wrong molecule.
Confirm the sequence before anything else, EDL versus Lys-Glu-Leu, then read the patent's animal and human examples against the kidney cell and rodent injury papers. The gap between those two piles is the real Ovagen story.
Identity
What it is
Ovagen is the tripeptide Glu-Asp-Leu, written EDL or H-Glu-Asp-Leu-OH, from the same Khavinson short-peptide tradition as the rest of the bioregulator family.
Its public identity is liver repair, and that identity comes from one document: a Russian patent describing liver explants, partial-hepatectomy rats, a cirrhosis model, and a 34-patient chronic-hepatitis example with claimed symptom improvement and bilirubin and ALT normalization. Patents are not peer-reviewed trials, and this one was never followed by a modern published one.
The checkable science sits elsewhere. The peer-reviewed EDL papers are kidney papers: cell cultures, organotypic rat kidney tissue, and rodent acute kidney-injury models, reporting effects on proliferation, p53, MMP-14, and renal-function markers. Respectable preclinical work, aimed at a different organ than the one on the label.
Then there is the market. U.S. sellers list research vials under the Ovagen name, and at least one of them specifies Lys-Glu-Leu, which is not EDL. When a name can mean two molecules, the name by itself tells you very little.
How people talk about it online
The visible U.S. market is research-chemical commerce: vial listings, purity and testing claims, and not-for-human-use disclaimers. The liver, GI, detox, and anti-aging language is extrapolated from the patent, the institute page, and short-peptide mechanism reviews.
The listings disagree with each other at the most basic level: EDL on one page, Lys-Glu-Leu on another, with formula inconsistencies reaching back to the patent's own chemistry line. Identity is not a pedantic concern here; it is the main event.
No consistent public Ovagen schedule shows up anywhere: no shared dose, route, or course pattern, just vial sizes and research-only positioning. That absence says a lot about how mature this market is.
Use context
Routes, doses, and cycle patterns
Ovagen has no FDA label or dependable modern human-use schedule. The concrete regimen details come from a Russian patent: parenteral H-Glu-Asp-Leu in animal liver models and a patent-described chronic-hepatitis example. U.S. seller pages describe research vials and conflicting sequence labels rather than human treatment schedules.
Human studies and product labels
Patent therapeutic-method range
- Purpose
- Liver-tissue regeneration claim
- Context
- Russian patent
- Route
- Parenteral
- Amount
- 0.01 to 100 micrograms per kilogram in the patent method language
- Frequency
- Once daily as needed in the patent method language
- Duration
- Patent method language does not define a fixed clinical course
This is patent language for H-Glu-Asp-Leu, not an approved label and not a modern human-use schedule.
Rat partial-hepatectomy example
- Purpose
- Liver regeneration after partial hepatectomy
- Context
- Russian patent animal example
- Route
- Subcutaneous
- Amount
- 0.1 micrograms per rat
- Frequency
- Given at 2 and 24 hours after surgery
- Duration
- Two injections in the described experiment
The patent reports more dividing liver cells in treated rats than saline controls. This is animal evidence, so it cannot answer whether Ovagen repairs human liver tissue.
Experimental cirrhosis example
- Purpose
- Liver biochemistry in a cirrhosis model
- Context
- Russian patent animal example
- Route
- Intramuscular
- Amount
- 0.5 micrograms per rat
- Frequency
- Monthly 5-day courses
- Duration
- Monthly courses in the described model
The patent describes movement in liver-related biochemical measures in animals. It is not treatment evidence for human cirrhosis.
Patent-described chronic-hepatitis example
- Purpose
- Chronic hepatitis symptoms and laboratory markers
- Context
- Russian patent human example
- Route
- Intramuscular
- Amount
- Patent report: severe exacerbation, 5 mg daily; moderate exacerbation, 10 micrograms daily; remission, 1 microgram daily
- Frequency
- Once daily
- Duration
- 10 days
The patent reports a 500-fold step from 10 micrograms to 5 mg between moderate and severe exacerbation, without explaining the reason for that discontinuity. It also reports symptom improvement and bilirubin/ALT normalization, but modern peer-reviewed confirmation was not located in the cited material.
Real-world discussion
No established community protocol
- Purpose
- Liver and GI discussion
- Context
- Bioregulator vendors, clinics, and forums
- Route
- Research vials and supplement-style products are marketed; no consistent route pattern is documented
- Amount
- No consistent community range is documented; U.S. vendors list 20 mg research vials
- Frequency
- Not established
- Duration
- Not established
No consistent public Ovagen schedule shows up in the collected material: no shared dose, route, or course pattern, just vial sizes and research-only positioning. Reported as context, not a recommendation.
What varies
- Identity: EDL and Lys-Glu-Leu are different tripeptides, so sequence confirmation changes the whole interpretation.
- Patent examples, kidney papers, institute marketing, and vendor listings should not be treated as the same quality of evidence.
- Route: patent examples discuss parenteral dosing, institute materials discuss a supplement product, and U.S. sellers list research vials.
- Amount: keep patent microgram-to-milligram examples separate from vendor vial strength.
- Product quality: purity percentages do not resolve sterility, endotoxin, representative lot testing, storage, or whether the correct peptide was made.
Human data
Human evidence
The entire public human record is one patent example: 34 chronic-hepatitis patients, daily intramuscular H-Glu-Asp-Leu for 10 days, with claimed symptom improvement and bilirubin and ALT normalization, and a dosing table that jumps 500-fold between moderate and severe disease without explanation. Around it sits institute marketing language for hepatitis, chemotherapy complications, toxic exposures, and older-adult liver support, with no methods to evaluate. No modern peer-reviewed human efficacy trial for Ovagen or EDL surfaced in these sources.
Evidence maturity
Ovagen's verifiable biology is preclinical kidney work; its only human material is a patent example, not a peer-reviewed trial.
Peer-reviewed cell, tissue, and rodent acute-kidney-injury studies report EDL effects on proliferation and renal markers.
A Russian patent adds animal liver-regeneration examples and one 34-patient chronic-hepatitis example with claimed symptom and lab improvements.
None surfaced for liver repair, kidney support, or longevity claims.
Institute supplement marketing and U.S. research vials disagree even on sequence, with EDL and Lys-Glu-Leu sold under the same name.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Patent-described chronic-hepatitis example | 34 patients, age 30 to 56, with chronic hepatitis | Patent-described randomized two-group example | H-Glu-Asp-Leu in patent literature | The patent translation reports daily intramuscular use for 10 days with claimed symptom improvement and normalization of bilirubin and ALT. | This is patent literature with limited clinical detail, not a modern peer-reviewed trial report. It is too weak to support an Ovagen hepatitis-treatment claim. | weak |
| Saint Petersburg Institute Ovagen product language | Not fully described in the institute summary | Institute / manufacturer-linked marketing statement | Cytogens line product | The institute describes Ovagen as useful in hepatitis, complications of chemotherapy or radiation, antibiotic side effects, toxic exposures, malnutrition, and liver support in older adults. | The institute summary lacks methods, endpoints, comparator details, and peer-reviewed trial data, so it cannot support a dependable treatment claim. | anecdotal |
| Kidney cell and rodent literature | Kidney cell cultures, organotypic rat kidney tissue, and rodent acute kidney injury models | Preclinical | EDL / short-peptide research material | Papers report effects on proliferation, apoptosis-related readouts, p53, MMP-14, renal function markers, proteinuria, sodium excretion, and antioxidant-enzyme activity. | These are not human outcome studies, so kidney treatment, longevity, detoxification, and general organ-repair claims in people remain weak. | preclinical |
Cautions
Safety and unknowns
- Ovagen-specific human safety is poorly characterized. A small patent example and animal toxicity language cannot substitute for a contemporary human safety record.
- The likely route matters. A supplement-style product, patent-described parenteral material, and U.S. research vial bring different sterility, endotoxin, impurity, excipient, storage, and administration risks.
- Peptide-related impurities, aggregation, immunogenicity, contamination, and inadequate human safety data are class-level concerns for compounded or gray-market peptides.
- Sequence mismatch can change risk. A product labeled Ovagen but containing Lys-Glu-Leu is not the same peptide as the EDL identity used in the patent and review literature.
Product quality
A vial label is only a starting point
The most important product-quality issue is identity. Public material ties Ovagen to EDL, but one U.S. seller lists Lys-Glu-Leu, a different tripeptide.
COA and purity language only helps if it confirms the actual sequence, lot, impurities, sterility expectations, and storage chain; otherwise it cannot connect a research vial to the patent material or institute product language.
Research-only and not-for-human-use disclaimers mean the seller is not presenting an FDA-approved medication or an established clinical product.
Sequence identity
EDL/H-Glu-Asp-Leu and Lys-Glu-Leu are different molecules, so the first issue is whether the material is describing the right peptide.
Regulatory context
A Russian parapharmaceutical listing, a patent, and a U.S. research-only vial are different product contexts with different controls and claims.
Analytical testing
Purity claims are only useful with method detail and lot traceability; injectable quality and clinical comparability require more than a purity percentage.
Sterility and endotoxin
These matter especially when internet discussion drifts toward injectable use; vendor marketing is not sterile clinical-product evidence.
Mechanism
How it is proposed to work
The Khavinson short-peptide hypothesis is that very small peptides may enter cells, interact with DNA or histones, and influence gene-expression patterns. For Ovagen/EDL, that mechanism helps explain liver and kidney research interest, not clinical efficacy.
A 2021 review lists EDL/Ovagen with renal-cell function, hepatoprotection, and DNA binding.
Kidney studies report EDL-related effects on cell-renewal and apoptosis-linked markers such as Ki-67, p53, MMP-14, and IL-8, plus rodent nephroprotection findings in gentamicin, ischemia/reperfusion, and cisplatin injury models.
General short-peptide papers describe DNA binding, histone interaction, gene-expression changes, methylation-related ideas, and possible ultrashort-peptide transport routes. Those ideas remain model-driven for Ovagen until human pharmacology and outcome studies catch up.
Ovagen (Glu-Asp-Leu) is a Khavinson-lineage tripeptide positioned for liver and GI claims, supported by the lineage's cell and animal work rather than controlled human studies.
FAQ
Common questions
What is ovagen?
Ovagen is a Khavinson-lineage bioregulator peptide positioned for liver and GI claims. Its evidence is the Russian bioregulator literature plus animal and cell work.
What do bioregulator courses look like?
No consistent public Ovagen schedule shows up: no shared dose, route, or course pattern, just 20 mg research vials and research-only positioning.
Is there human evidence?
Nothing meeting controlled-trial standards. The claims rest on the lineage's own publications.
Details
Technical details
Sources
References
- 1.
RU2297239C1 Ovagen patent. RU2297239C1, Google Patents translation
Core liver-regeneration identity, chemistry, animal examples, patent human example, regimen described in the study
- 2.
2015 rat kidney tissue study. Chalisova et al. 2015, PubMed PMID 26033601
Kidney tissue culture proliferation/apoptosis study
- 3.
2017 rat AKI nephroprotection preview. Zamorskii et al. 2017, Springer preview
Rat acute kidney-injury nephroprotection with EDL
- 4.
2021 short-peptide systematic review. Khavinson et al. 2021 systematic review
Lists EDL/Ovagen with renal-cell function, hepatoprotection, DNA binding
- 5.
2016 gene-expression paper. Khavinson et al. 2016, Short Peptides Regulate Gene Expression
General DNA-binding and gene-expression mechanism framework
- 6.
2022 transport review. Khavinson et al. 2022 transporter review
General ultrashort-peptide transport plausibility
- 7.
Saint Petersburg Institute Ovagen page. Saint Petersburg Institute Cytogens page
Official institute marketing, registration number, product characterization
- 8.
Verified Peptides Ovagen listing. Verified Peptides Ovagen page
Gray-market seller, research-only positioning, sequence conflict
- 9.
Core Peptides Ovagen listing. Core Peptides Ovagen page
Gray-market seller, EDL identity, not 503A/503B
- 10.
PubChem Lys-Glu-Leu record. PubChem Lys-Glu-Leu page
Confirms Lys-Glu-Leu is a distinct tripeptide
- 11.
FDA compounding Q&A. FDA Compounding Q&A
Compounded drugs are not FDA-approved and quality is not pre-verified
- 12.
FDA bulk-substance safety page. FDA bulk-substance safety-risk page
Peptide-related impurity, immunogenicity, limited-human-data concerns